BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23448298)

  • 1. A potent and highly efficacious Bcl-2/Bcl-xL inhibitor.
    Aguilar A; Zhou H; Chen J; Liu L; Bai L; McEachern D; Yang CY; Meagher J; Stuckey J; Wang S
    J Med Chem; 2013 Apr; 56(7):3048-3067. PubMed ID: 23448298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression.
    Chen J; Zhou H; Aguilar A; Liu L; Bai L; McEachern D; Yang CY; Meagher JL; Stuckey JA; Wang S
    J Med Chem; 2012 Oct; 55(19):8502-14. PubMed ID: 23030453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.
    Zhou H; Aguilar A; Chen J; Bai L; Liu L; Meagher JL; Yang CY; McEachern D; Cong X; Stuckey JA; Wang S
    J Med Chem; 2012 Jul; 55(13):6149-61. PubMed ID: 22747598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The small-molecule compound BM-1197 inhibits the antiapoptotic regulators Bcl-2/Bcl-xL and triggers apoptotic cell death in human colorectal cancer cells.
    Ye L; Yuan G; Xu F; Sun Y; Chen Z; Chen M; Li T; Sun P; Li S; Sun J
    Tumour Biol; 2015 May; 36(5):3447-55. PubMed ID: 25542230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x
    Balachander SB; Criscione SW; Byth KF; Cidado J; Adam A; Lewis P; Macintyre T; Wen S; Lawson D; Burke K; Lubinski T; Tyner JW; Kurtz SE; McWeeney SK; Varnes J; Diebold RB; Gero T; Ioannidis S; Hennessy EJ; McCoull W; Saeh JC; Tabatabai A; Tavana O; Su N; Schuller A; Garnett MJ; Jaaks P; Coker EA; Gregory GP; Newbold A; Johnstone RW; Gangl E; Wild M; Zinda M; Secrist JP; Davies BR; Fawell SE; Gibbons FD
    Clin Cancer Res; 2020 Dec; 26(24):6535-6549. PubMed ID: 32988967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
    Bruncko M; Oost TK; Belli BA; Ding H; Joseph MK; Kunzer A; Martineau D; McClellan WJ; Mitten M; Ng SC; Nimmer PM; Oltersdorf T; Park CM; Petros AM; Shoemaker AR; Song X; Wang X; Wendt MD; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
    J Med Chem; 2007 Feb; 50(4):641-62. PubMed ID: 17256834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL, (-)-Gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line.
    Mohammad RM; Wang S; Banerjee S; Wu X; Chen J; Sarkar FH
    Pancreas; 2005 Nov; 31(4):317-24. PubMed ID: 16258364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-X
    Roy MJ; Vom A; Okamoto T; Smith BJ; Birkinshaw RW; Yang H; Abdo H; White CA; Segal D; Huang DCS; Baell JB; Colman PM; Czabotar PE; Lessene G
    J Med Chem; 2021 May; 64(9):5447-5469. PubMed ID: 33904752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding affinities based upon a new scaffold.
    Zhou H; Chen J; Meagher JL; Yang CY; Aguilar A; Liu L; Bai L; Cong X; Cai Q; Fang X; Stuckey JA; Wang S
    J Med Chem; 2012 May; 55(10):4664-82. PubMed ID: 22448988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model.
    Arnold AA; Aboukameel A; Chen J; Yang D; Wang S; Al-Katib A; Mohammad RM
    Mol Cancer; 2008 Feb; 7():20. PubMed ID: 18275607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel small-molecule inhibitors of Bcl-XL to treat lung cancer.
    Park D; Magis AT; Li R; Owonikoko TK; Sica GL; Sun SY; Ramalingam SS; Khuri FR; Curran WJ; Deng X
    Cancer Res; 2013 Sep; 73(17):5485-96. PubMed ID: 23824742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo.
    Sun Y; Wu J; Aboukameel A; Banerjee S; Arnold AA; Chen J; Nikolovska-Coleska Z; Lin Y; Ling X; Yang D; Wang S; Al-Katib A; Mohammad RM
    Cancer Biol Ther; 2008 Sep; 7(9):1418-26. PubMed ID: 18769131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo.
    Lin J; Wu Y; Yang D; Zhao Y
    Oncol Rep; 2013 Aug; 30(2):731-8. PubMed ID: 23708869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins.
    Tang G; Yang CY; Nikolovska-Coleska Z; Guo J; Qiu S; Wang R; Gao W; Wang G; Stuckey J; Krajewski K; Jiang S; Roller PP; Wang S
    J Med Chem; 2007 Apr; 50(8):1723-6. PubMed ID: 17378545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
    Gautschi O; Tschopp S; Olie RA; Leech SH; Simões-Wüst AP; Ziegler A; Baumann B; Odermatt B; Hall J; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 2001 Mar; 93(6):463-71. PubMed ID: 11259472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapies for epithelial cancers: in vivo efficacy of the BCL-2/BCL-XL inhibitor 2-MeAA.
    Schwartz PS; Hockenbery DM
    Cancer Biol Ther; 2007 Mar; 6(3):465-6. PubMed ID: 17471026
    [No Abstract]   [Full Text] [Related]  

  • 17. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer.
    Jin J; Xiong Y; Cen B
    Anticancer Drugs; 2017 Nov; 28(10):1141-1149. PubMed ID: 28885267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a Novel BCL-X
    Pal P; Thummuri D; Lv D; Liu X; Zhang P; Hu W; Poddar SK; Hua N; Khan S; Yuan Y; Zhang X; Zhou D; Zheng G
    J Med Chem; 2021 Oct; 64(19):14230-14246. PubMed ID: 34533954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.